No abstract

implanted ports and therefore had a Vascath placed on the morning of pheresis. Twelve patients completed pheresis and reached target CD34 collection through double lumen CVL. One patient was unable to complete pheresis via his CVL and had a successful pheresis the following day after Vascath placement. Median inlet flow rates were significantly lower in patients undergoing pheresis with a double lumen CVL when compared to patients undergoing pheresis via Vascath and there was a significantly higher rate of pressure error readings in patients with CVLs. Time from admission to start of pheresis was significantly less in patients who underwent pheresis with a CVL. There was no significant difference in time on machine, CD34/kg collected, or number of days of pheresis. Conclusion: Hematopoietic stem cell pheresis utilizing double lumen CVL is feasible with the potential benefits of shorter hospitalization and avoidance of second line placement.Melphalan 200 mg/m 2 IV is the most common conditioning regimen for AHCT in MM. Conventional melphalan formulations (eg, Alkeran) have marginal solubility, limited chemical stability and require PG as a co-solvent, which is associated with renal dysfunction and arrhythmias. Captisolenabled Melphalan HCL (CE-Melphalan) is a PG-free formulation of melphalan that incorporates Captisol, a modified cyclodextrin that improves its solubility, stability and bioavailability. In a previous Phase 2 study, CE-Melphalan was shown to be bioequivalent to Alkeran. Methods: This Phase II, open-label study enrolled 61 pts with MM who received 200 mg/m 2 of CE-Melphalan (100 mg/m 2 / day x 2) followed by AHCT. Most subjects were male (57%) with a median age of 62.0 years (range 32-73), including 56 (92%) subjects who received upfront AHCT and 5 (8%) after relapse (Table 1). Median lines of prior therapy was 3 (range 2-16). High risk cytogenetics in 6 (10%) pts. Disease status at pre-treatment included CR in 3 subjects, VGPR in 27 and PR in 20 subjects.

No abstract